

Systematic Review

The efficacy of *n*-3 fatty acids DHA and EPA (fish oil) for perinatal depression

Linda A. W. Jans^{1*}, Erik J. Giltay² and A. J. Willem Van der Does^{1,2}

¹Institute of Psychology, Leiden University, Wassenaarseweg 52, 2333 AK Leiden, The Netherlands

²Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands

(Received 24 March 2010 – Revised 17 August 2010 – Accepted 14 September 2010 – First published online 16 November 2010)

Depressive symptoms are common during pregnancy and the post-partum period. Although essential *n*-3 PUFA may have beneficial effects on depression, it remains unclear whether they are also effective for perinatal depression. The purpose of the present study was to assess the efficacy of *n*-3 supplementation for perinatal depression, by performing a meta-analysis on currently available data. After a thorough literature search, we included seven randomised controlled trials in the meta-analysis, all with EPA and/or DHA supplementation. Most studies were judged to be of low-to-moderate quality, mainly due to small sample sizes and failure to adhere to Consolidated Standards of Reporting Trials guidelines. Some studies were not primarily designed to address perinatal depression. A total of 309 women on *n*-3 fatty acid supplementation were compared with 303 women on placebo treatment. *n*-3 Supplementation was not found to be significantly more effective than placebo at post-treatment with a pooled effect size (Hedges's *g*) of -0.03 (95% CI $-0.18, 0.13$; $P=0.76$) using a fixed-effects model. Heterogeneity was low-to-moderate ($I^2 = 30\%$). In a subgroup analysis of three small studies of pregnant women with major depression, there was some indication of effectiveness (effect size 0.17 ; 95% CI $-0.21, 0.55$). In conclusion, the question of whether EPA and DHA administration is effective in the prevention or treatment of perinatal depression cannot be answered yet. Future research should focus on women who are clinically depressed (or at risk). The quality of research in this area needs to improve.

Perinatal depression: Fish oil: *n*-3 PUFA: Meta-analysis

In recent years, *n*-3 PUFA supplementation has been associated with several health benefits. The *n*-3 fatty acids DHA (22:6*n*-3) and EPA (20:5*n*-3), found primarily in seafood, are essential constituents of cell membranes, and are critical for normal brain function^(1–3). DHA is highly concentrated in membrane phospholipids and is important in neuronal membrane stability, neuroplasticity, signal transduction and neurotransmission^(4,5). EPA, although comprising only a small percentage of total brain fatty acid composition, is important in balancing immune and inflammation functions because the eicosanoids produced from EPA are anti-inflammatory⁽⁶⁾.

There is increasing evidence that *n*-3 PUFA are involved in mood disorders. Epidemiological studies have shown that fish consumption is inversely associated with depression^(7–9). In addition, depressed patients show several alterations in *n*-3 PUFA, and particularly DHA, compared with healthy controls^(7,10–12). There is also evidence that *n*-3 PUFA are of therapeutic benefit as an adjunctive treatment in depression^(13–15). Meta-analyses of clinical trials^(16,17) have shown a moderate anti-depressant effect of DHA and/or EPA, in addition to anti-depressant medication, after 4–16

weeks of treatment. However, there was substantial heterogeneity among trials, and several double-blind randomised controlled trials^(18–20) found no beneficial effect of *n*-3 PUFA on depression.

Pregnancy and the post-partum period provide an excellent opportunity to examine the relationship between *n*-3 PUFA and depression. Pregnancy leads to several changes in PUFA status, including a depletion of maternal plasma DHA under normal dietary conditions^(21,22) that persists after delivery^(23,24). This suggests that normal dietary intake may be insufficient during the perinatal period. During pregnancy, maternal DHA is selectively transferred to the fetus to support optimal fetal development, and after birth, breast milk provides DHA to the infant. Mothers may be at higher risk for post-partum depression when they become depleted of *n*-3 PUFA, and especially of DHA⁽²⁵⁾. Depression is quite common during pregnancy and in the post-partum period. A large longitudinal cohort study found a combined prevalence of depression of 25% during pregnancy and post-partum, with higher prevalence during pregnancy than during post-partum⁽²⁶⁾. In terms of post-partum depression,

Abbreviations: BDI, Beck Depression Inventory; EPDS, Edinburgh Postnatal Depression Scale; HAM-D, Hamilton Depression Rating Scale; ITT, intention-to-treat.

* **Corresponding author:** Dr L. A. W. Jans, fax +31 71 527 4678, email janslaw@fsw.leidenuniv.nl

a meta-analysis of fifty-nine studies reported a prevalence rate of 13 %⁽²⁷⁾.

Increased dietary intake of *n*-3 PUFA results in increased *n*-3 levels in maternal plasma and breast milk⁽²⁸⁾, which might play a role in preventing or ameliorating depressive symptoms during pregnancy and the post-partum period. A meta-analysis of cross-national epidemiological data showed that lower seafood consumption and lower DHA content in mother's milk were associated with higher rates of post-partum depression⁽²⁹⁾. Several studies support an association between low *n*-3 intake from seafood or low *n*-3 PUFA status and increased risk of depressive symptoms during pregnancy⁽³⁰⁾ or in the post-partum period⁽³¹⁾, but results are mixed^(32–34). In recent years, several intervention studies have been published. The question we attempt to answer in the present systematic review and meta-analysis is whether treatment with *n*-3 PUFA prevents or reduces symptoms of depression during and directly after pregnancy.

Methods

Inclusion criteria for the systematic review and meta-analysis were as follows: intervention with at least one *n*-3 PUFA or fish oil supplement; intervention period at least 4 weeks; mood or depression as a primary or secondary outcome measure using validated instruments on at least one occasion at the end of or after the intervention period. Participants had to be pregnant or post-partum women, either depressed or non-depressed. Furthermore, studies had to be placebo-controlled, double-blinded and randomised.

The initial search aimed to identify all reports of *n*-3 or fish oil interventions during pregnancy or post-partum with mood or depression being measured at least once; study quality was assessed after the search. Databases searched for this review included Embase.com, Medline, PubMed, PsycINFO, Web of Science, World Health Organization Reproductive Health Library and the Cochrane's Central Register of Controlled Trials, until December 2009. Search terms included a wide range of synonyms for perinatal (pregnan* or prenatal or antenatal or perinatal or postnatal or peripartum or post-partum); fish fatty acids (fish or DHA or docosahexaenoic acid or EPA or eicosapentaenoic acid or α -linolenic acid (ALA) or α -linolenic acid or omega-3 fatty acid or *n*-3 fatty acid); randomised controlled trials (supplemen* or randomised or RCT or trial or intervention or treatment); depression (depress* or mood) both in Medical Subject Heading (MeSH) or in index terms and text words. Reference lists of included studies and relevant reviews were searched, and reviews and meta-analyses concerning the treatment of perinatal depression were screened for additional relevant studies. Furthermore, attempts were made to locate unpublished material by searching conference abstracts and clinical trial registers for unpublished ongoing research (<http://www.controlled-trials.com>; <http://www.wombatcollaboration.net>). Authors of original reports were contacted to ask them for additional information if needed.

Meta-analysis

For most studies, the pre- to post-treatment effect sizes were calculated by subtracting the average post-treatment score

from the average pre-treatment score and dividing the result by the pooled standard deviations of both groups or by using the average difference between the pre- and post-treatment scores in both groups. The standardised mean difference corrected for bias (Hedges's *g*) was used (with the correction factor $J: 1 - (3/(4 \times df - 1))$). Several studies reported more than one outcome measure for depression, e.g. Edinburgh Postnatal Depression Scale (EPDS), Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HAM-D) and Montgomery-Åsberg Depression Rating Scale. We selected the EPDS because it is the most appropriate scale for this population. We selected the BDI from Mattes *et al.*⁽³⁵⁾ as the EPDS was not used in that study. Each study was represented by only one effect size in the meta-analysis. When available, intention-to-treat (ITT) data were used in the meta-analysis. When means or mean differences and standard deviations were not reported, we used other statistics (i.e. *P* value) to compute the effect sizes, which applied to one study⁽³⁶⁾. To calculate the pooled mean effect sizes, we used the computer program Comprehensive Meta-analysis (version 2.2.021; Biostat, Englewood, NJ, USA). The pooled mean effect sizes using both the fixed- and random-effects models were computed. In the random-effects model, the included studies are seen as a sample drawn from a population of studies, resulting in wider 95 % CI. As an indicator of homogeneity, the *Q*-statistic was calculated, and as an indicator of heterogeneity, the *I*²-statistic (with 0 % indicating no, 25 % indicating low, 50 % indicating moderate and 75 % indicating high heterogeneity) was calculated. Selection bias was visually examined using the funnel plot.

Results

The literature search resulted in 508 citations. Relevant reviews were screened for potentially relevant references. The majority of these citations and references were excluded in the first screening phase. A total of eleven intervention reports were retrieved for detailed evaluation in the second screening phase. Of these eleven intervention papers, four were additionally excluded due to our inclusion and exclusion criteria^(37–40), and seven randomised, placebo-controlled, double-blind trials were included in the meta-analysis^(35,36,41–45). For three studies, depression was not the primary outcome measure^(35,36,41). All included studies used marine-derived *n*-3 PUFA interventions; some used fish oil^(35,36,44), some DHA^(41,43), and some a combination of DHA and EPA^(42,45). Therefore, the remainder of the present paper focuses on these fatty acids. Fig. 1 shows a detailed flow chart of the results of the literature search.

Description of included studies

A detailed outline of the intervention studies that were included in the meta-analysis is presented in Table 1. In the study by Doornbos *et al.*⁽⁴¹⁾, apparently healthy pregnant women received either DHA (220 mg), DHA + arachidonic acid (220 mg each) or placebo daily from enrolment (weeks 14–20 of pregnancy) until 3 months after delivery. Depression was assessed with the EPDS in weeks 16 and 36 of pregnancy and 6 weeks post-partum. Erythrocyte fatty acid analysis was




Fig. 1. Flow chart of the results of the literature search.

performed at enrolment and in week 36 of pregnancy. A total of 182 women were included in the trial; 111 participants completed all measurements. *n*-3 PUFA levels in erythrocytes were significantly higher in the supplemented groups. EPDS scores of 12 or higher were found in eight women (6.7%) in week 36 of pregnancy and in seven women (5.9%) at 6 weeks post-partum. Doornbos *et al.*⁽⁴¹⁾ reported median EPDS and delta EPDS scores, as the data were skewed. For the meta-analysis, we used the mean delta EPDS scores (completers only) provided by the authors, as delta scores tend to be more normally distributed. Only data of the DHA group and the placebo group were included in the meta-analysis.

In the study by Mattes *et al.*⁽³⁵⁾, ninety-eight pregnant women with allergic disease, but otherwise healthy, were recruited before 20 weeks of pregnancy. The participants received either a daily supplement of 4 g fish oil (56% DHA and 27.7% EPA) or placebo from week 20 of pregnancy until delivery. Depression was measured with the BDI at 20 weeks of gestation and in the first week after delivery. Blood samples for fatty acid analyses were collected at 20 weeks of gestation and immediately after delivery. Complete data were available for seventy-five participants. At 20 weeks of gestation (before dietary intervention), 22.2% of all participants had a BDI score of 10 or higher. Fish oil supplementation was associated with a significant increase in *n*-3 PUFA levels and the *n*-3:*n*-6 ratio, together with a proportional fall in *n*-6 PUFA levels (reported in Dunstan *et al.*⁽⁴⁶⁾). Mean delta BDI scores (completers only), provided by the authors, were used in the meta-analysis.

In the study by Su *et al.*⁽⁴⁵⁾, pregnant women with DSM-IV major depressive disorder, onset between weeks 16 and 32 of gestation, were given gelatin capsules containing either *n*-3 PUFA (2.2 g EPA + 1.2 g DHA) or placebo for 8 weeks.

After a single-blind placebo run-in of 1 week, four participants who had a decrease of 20% or more in HAM-D scores did not proceed to the randomisation phase. The HAM-D, EPDS and BDI were completed before the placebo run-in, at baseline and at weeks 2, 4, 6 and 8 of the intervention period. Blood samples for *n*-3 fatty acid analysis were taken before the placebo run-in and at week 8 of the intervention. Of the thirty-six included participants, twenty-four completed all measurements. *n*-3 Supplementation induced a significant increase in the erythrocyte DHA level, but not in the EPA level. Mean pre- and post-EPDS scores (baseline and week 8) presented in the paper (ITT) were used in the meta-analysis. The ITT population included all participants who had been evaluated on more than two visits.

In the study by Freeman *et al.*⁽⁴²⁾, pregnant (12–32 weeks) and post-partum (within 6 months of childbirth) women with major depressive disorder (DSM-IV criteria) and EPDS score 9 or higher, received either *n*-3 fatty acids (1.1 g EPA + 0.8 g DHA) or maize oil (placebo; with 1% fish oil for blinding purposes) for 8 weeks. Moreover, all patients received six 30 min sessions of individual psychotherapy during the trial. Depression was assessed with the HAM-D and EPDS at baseline and every 2 weeks during the treatment period. Of the fifty-nine participants, fifty-one completed at least two assessments. Mean pre- and post-EPDS scores (baseline and week 8; pregnant and post-partum women combined) presented in the paper were used in the meta-analysis, including all patients who completed baseline and at least one follow-up assessment.

In the study by Rees *et al.*⁽⁴⁴⁾, women in their third trimester of pregnancy or up to 6 months post-partum, with a current episode of depression or dysthymia, were treated with fish oil (6 g; 27.3% DHA, 6.9% EPA, 80 mg vitamin E) or placebo for 6 weeks. Blood samples for plasma fatty acid analyses were taken at baseline and at the end of the study. EPDS, HAM-D and Montgomery-Åsberg Depression Rating Scale data were collected weekly. Of the twenty-six women who entered the study, twenty-one completed all the measurements. Mean pre- and post-EPDS scores (baseline and week 6; pregnant and post-partum women together) presented in the paper were used in the meta-analysis. The ITT population included all subjects who started the study (at least baseline session).

In a four-arm study by Krauss-Etschmann *et al.*⁽³⁶⁾, apparently healthy pregnant women received fish oil (500 mg DHA and 150 mg EPA); 400 µg methyltetrahydrofolic acid; both or placebo from week 22 of gestation until delivery. Plasma fatty acid analyses were performed at baseline (gestation week 20), gestation week 30 and at delivery. Depression was measured with the EPDS at delivery and/or at 2 months post-partum; this is not clearly described in the paper, and the authors did not provide additional information on repeated requests. Of the 311 participants enrolled, 270 completed the study. The fish oil supplementation increased maternal DHA and EPA during the supplementation period. Because the EPDS data are not included in the paper and the authors declined to provide these data, this study was included in the meta-analysis with a *P* value of 1 (as it is mentioned in the paper that no statistically significant group difference was found). A separate sensitivity analysis was run without these data. In the meta-analysis, the DHA

Table 1. Outline of the included studies

	Llorente <i>et al.</i> ⁽⁴³⁾	Krauss-Etschmann <i>et al.</i> ⁽³⁶⁾	Rees <i>et al.</i> ⁽⁴⁴⁾	Freeman <i>et al.</i> ⁽⁴²⁾	Su <i>et al.</i> ⁽⁴⁵⁾	Mattes <i>et al.</i> ⁽³⁵⁾	Doornbos <i>et al.</i> ⁽⁴¹⁾
Country	USA	Germany, Hungary, Spain	Australia	USA	Taiwan	Australia	The Netherlands
Intervention type and daily dose	200 mg DHA/ placebo	FO (500 mg DHA and 150 mg EPA)/400 µg 5-MTHF/both/ placebo	6 g FO (27.3% DHA, 6.9% EPA, 80 mg vitamin E)/placebo	1.1 g EPA + 0.8 g DHA/placebo. Supportive psychotherapy	2.2 g EPA + 1.2 g DHA/placebo	4 g FO (56% DHA and 27.7% EPA)/ placebo	DHA (220 mg)/DHA + AA (220 mg each)/ placebo
Intervention duration	4 months	Week 22 until delivery	6 weeks	8 weeks	8 weeks	Week 20 until delivery	From weeks 14–20 until 3 months post-partum
Intervention period	Post-partum	Pregnancy	Pregnancy and/or post-partum	Pregnancy or post-partum (data separately)	Pregnancy	Pregnancy	Pregnancy and post-partum
<i>n</i> included in analysis	44/45	69/65/64/72	13/13	28/23	17/16 ITT; 13/11 PP	36/37	38/30/32
Subjects' fish consumption	Not mentioned; no FO supplement	Not mentioned; no FO supplement	Max. three oily fish portions a week; no FO supplements	Not mentioned, mean fish intake < 0.5 servings/month	Not mentioned	Max. two fishmeals a week; no FO supplements	Not mentioned, mean intake fish 0.94 times/week, fatty fish 0.45
Subjects' baseline mood status	Healthy	Healthy	Major depression (diagnosed)	Major depression (diagnosed)	Major depression (diagnosed, onset in weeks 16–32)	Healthy	Healthy
Other	Breast-feeding	Supplement of vitamins and minerals	–	Supportive psychotherapy	–	Allergic disease	Supplement of vitamins and minerals
Psychopharmaca or psychotherapy	None	None	None	None	No medication for at least 1 month	None	None
Mood measure (number of measurements)	BDI (4) in all; EPDS (1) and SCID (1) in subgroup	EPDS (1 or 2)	EPDS (7), HAM-D (7), MADRS (7)	EPDS (5), HAM-D (5)	HAM-D (6), EPDS (6), BDI (6)	BDI (2)	EPDS (3)
Presented data	PP, completers only	None	ITT; prenatal and post-partum combined	ITT; prenatal and post-partum combined and separately	ITT and PP	PP, completers only	PP, completers only

FO, fish oil; 5-MTHF, methyltetrahydrofolic acid (folate); AA, arachidonic acid; ITT, intention-to-treat; Max., maximum; BDI, Beck Depression Inventory; EPDS, Edinburgh Postnatal Depression Scale; SCID, Structured Clinical Interview for DSM Disorders; HAM-D, Hamilton Rating Scale for Depression; MADRS, Montgomery–Åsberg Depression Rating Scale; PP, per protocol.

Table 2. Methodological quality characteristics of the included studies

	Llorente <i>et al.</i> ⁽⁴³⁾	Krauss-Etschmann <i>et al.</i> ⁽³⁶⁾	Rees <i>et al.</i> ⁽⁴⁴⁾	Freeman <i>et al.</i> ⁽⁴²⁾	Su <i>et al.</i> ⁽⁴⁵⁾	Mattes <i>et al.</i> ⁽³⁵⁾	Doornbos <i>et al.</i> ⁽⁴¹⁾
Design (no. of groups)	Parallel groups (2)	Parallel groups (4)	Parallel groups (2)	Parallel groups (2)	Parallel groups (2)	Parallel groups (2)	Parallel groups (3)
Randomisation	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Randomisation method	Computer-generated randomisation scheme	Block-randomised, allocation by drawing envelopes	Computer-based random number generation method	Not mentioned	Not mentioned	Block-randomised according to parity, pre-pregnancy BMI, age and allergy	Block-randomised
Placebo type	Not mentioned	Not mentioned	Sunola oil	Maize oil with 1 % fish oil	Olive oil ethyl esters	Olive oil	Soya bean oil
Matched placebo	Not mentioned	Yes, appearance and contents of sachets	Yes, peppermint oil added to all capsules	Yes, 1 % fish oil added to placebo	Yes, dose, smell (deodorised), flavour (orange)	Yes, dose and appearance	Not mentioned
Blinding	Double-blind	Double-blind	Double-blind	Double-blind	Double-blind	Double-blind	Double-blind
Blinding evaluated	Not mentioned	Not mentioned	Yes, reported fishy or peppermint aftertaste	Not mentioned	Not mentioned	Not mentioned	Not mentioned
Single-blind placebo run-in	No	No	No	No	Yes, 1 week; placebo responders excluded	No	No
Adherence assessed	Number of returned capsules; blood fatty acid analysis	Compliance questionnaire; number of returned sachets; blood fatty acid analysis	Dietary assessment; compliance questionnaire; blood fatty acid analysis	Inquiry regarding missed doses and pill counts at each visit	Blood fatty acid analysis; no information about compliance	Blood fatty acid analysis	Blood fatty acid analysis
Sample size calculation done	Not mentioned	Yes	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
No. of included women	138	311	26	59	36	98	182
Reported drop-out	26.8%	13.2%	19.2%	33.9%	33.3%	17.3%	34.6%
Intention-to-treat analysis	No	No	Yes, all subjects with at least baseline	No, subjects with baseline and at least one follow-up	No, subjects with more than two visits	No	No
Included in analysis	71.7%	Unknown for EPDS data	100%	86.4%	91.6%	74.5%	54.9%

EPDS, Edinburgh Postnatal Depression Scale.

n-3 Fatty acids and perinatal depression

and DHA+methyltetrahydrofolic acid groups were compared with the placebo and methyltetrahydrofolic acid groups.

In the study by Llorente *et al.*⁽⁴³⁾ apparently healthy pregnant women received either 200 mg/d of DHA or placebo for 4 months, starting within a week of delivery. Plasma fatty acids were measured shortly before delivery and 4 months after delivery. The BDI was completed at baseline, 3 weeks, 2 months and 4 months after delivery. Of the 138 women enrolled, eighty-nine completed all measurements. Plasma DHA levels after 4 months were significantly higher in the DHA group than in the placebo group. Mean pre- and post-BDI scores (completers only; baseline and 4 months post-partum) presented in the paper were used in the meta-analysis.

Characteristics of study quality are shown in Table 2. Although all studies were randomised, double-blinded and placebo-controlled, the quality of the included studies was not always optimal. Placebo type was not always mentioned, and it was not always clear whether the placebo matched the active treatment in terms of dose, appearance, smell and flavour. Moreover, only one study mentioned evaluating whether the blinding was adequate. It is important to verify adequate blinding because *n-3* supplements can have a fishy aftertaste, which may reduce the success of blinding. The number of participants was low in most studies. In one study, which was the largest study, depression was presumably measured on only one occasion⁽³⁶⁾. In contrast with Consolidated Standards of Reporting Trials guidelines, ITT analyses were presented in only one of the seven studies⁽⁴⁴⁾. Two other papers^(42,45) presented their analyses as ITT analyses (Table 1), but closer inspection revealed that, in these studies, only participants who completed at least two⁽⁴²⁾ or more than two⁽⁴⁵⁾ visits were included. It is also important to note that most studies measured a change in mood or depressive symptoms, but not a change in the diagnostic status of perinatal depression.

Meta-analysis

We could compare the EPA and/or DHA pre- to post-treatment depression change in seven studies, totalling 612 subjects (Fig. 2). A fixed-effect meta-analysis on all contrasts was conducted (Fig. 2 and Table 3) resulting in a mean pooled effect size of -0.03 (95% CI $-0.18, 0.13$; $P=0.76$) and

-0.02 (95% CI $-0.23, 0.19$; $P=0.86$) using a random-effects model. The hypothesis of homogeneity was not rejected because a non-significant Q value was found ($Q = 8.54$, $P=0.20$; $I^2 = 29.7$). The effect sizes and 95% CI of the included studies are plotted in Fig. 2, which shows that the 95% CI of one study did not overlap with the CI of the pooled mean effect size. When only the EPDS was used as the outcome measure, the pooled mean effect size was 0.02 ($n 450$; 95% CI $-0.17, 0.21$; $P=0.83$ using a fixed-effects model). Repeating the analyses while excluding the trial by Krauss-Etschmann *et al.*⁽³⁶⁾ resulted in a similar pre- to post-treatment effect size (Hedges's $d = -0.05$; $n 342$; 95% CI $-0.26, 0.17$; $P=0.68$; Table 3). Therefore, the pooled mean effect size was non-significant and indicated no or a small pre- to post-treatment decrease in the perinatal depression. The pooled effect size of the three trials in depressed patients showed some indication of effectiveness (effect size 0.17 ; 95% CI $-0.21, 0.55$), though not statistically significant (Table 3).

The funnel plot (Fig. 3) indicated no strong evidence for the presence of publication bias or systematic heterogeneity. Although the positive study by Su *et al.*⁽⁴⁵⁾ was an outlier, the other studies fitted a rather symmetric inverted funnel shape.

Discussion

The meta-analysis showed no beneficial effect of *n-3* PUFA over placebo on symptoms of perinatal depression. The pre- to post-treatment effect sizes were consistently close to zero, indicating no significant change in depressive symptoms during fish oil, EPA and/or DHA administration, except for one study⁽⁴⁵⁾. In this study⁽⁴⁵⁾, prenatally depressed Taiwanese women received a relatively large dose of DHA and, especially, EPA daily for 8 weeks. This was the only study in which a single-blind placebo run-in of 1 week was used; the participants who showed a decrease in the HAM-D score of 20% or more were excluded. Because only one randomised double-blind placebo-controlled study reported a beneficial effect of *n-3* supplementation on perinatal depression, it is important to replicate this finding using a larger study population and also in other ethnic populations.




Fig. 2. Standardised effect sizes of *n-3* fatty acids DHA and EPA compared with that of placebo oil and 95% CI of the included studies and the pooled effect size. Std diff, standardised difference.

Table 3. Meta-analyses of studies examining the effects of n-3 fatty acids DHA and EPA (i.e. fish oil) on perinatal depressive symptoms: overall results and subgroup analyses


	No. of studies	No. of n-3/placebo	Hedges's <i>g</i>	95% CI	<i>Q</i>	<i>I</i> ² (%)	<i>P</i> value for heterogeneity	<i>P</i> value for difference between subgroups
All studies								
Fixed	7	309/303	-0.025	-0.184, 0.134	8.535	29.70	0.20	
Random	7	309/303	-0.019	-0.227, 0.189				
With Krauss-Etschmann <i>et al.</i> ⁽³⁶⁾ excluded	6	176/166	-0.045	-0.259, 0.169	8.459	40.89	0.13	
Intervention period								
Pregnancy	3	186/190	0.020	-0.183, 0.223	6.799	70.59	0.03	0.49
Pregnancy and post-partum	4	123/113	-0.096	-0.353, 0.160	1.250	0.00	0.74	
Mood status								
Healthy women	4	251/251	-0.066	-0.241, 0.109	1.03	0.00	0.79	0.27
Depression	3	58/52	0.169	-0.212, 0.550	6.297	68.24	0.04	

The results of the present meta-analysis are not in line with two previous meta-analyses on the efficacy of n-3 PUFA for unipolar major depression, which found n-3 PUFA to be superior to placebo treatment^(17,47). It should be noted, however, that significant heterogeneity was observed in the latter two meta-analyses. Meta-analyses in which samples other than depressed patients were also included⁽⁴⁸⁾ (and recent updates^(19,49)) found little evidence for a beneficial effect of n-3 PUFA on depressed mood. However, in two of these meta-analyses^(48,49), a separate analysis including only trials that enrolled populations with diagnosed depressive illness did show a beneficial effect of n-3 PUFA supplementation on depressed mood, although substantial heterogeneity remained. This indicates that a possible effect may be restricted to depressed populations, and that there may be as-yet unknown moderators of the effect within depressed populations.

Of the individual studies included in this meta-analysis, most showed limitations in methodological quality. In fact, several authors mention limitations or advise caution in the interpretation of results^(35,41-45). In the study by Doornbos *et al.*⁽⁴¹⁾, reported limitations included the relatively small sample size caused by a high drop-out and the relatively low DHA dosage. In addition, the EPDS was used to measure perinatal depression, which is a self-report questionnaire that is developed as a screening tool and not as an instrument to assess the effects of interventions. This latter concern is also mentioned by Llorente *et al.*⁽⁴³⁾. Su *et al.*⁽⁴⁵⁾ point out that interpretation of the results is complicated by the high discontinuation rate and the lack of information about compliance, which might have biased the results. In the study by Freeman *et al.*⁽⁴²⁾, both groups showed significant improvement. The psychotherapy intervention may have obscured any differences in effect between treatment groups. Furthermore, the small number of subjects was a limitation of that study. In the study by Rees *et al.*⁽⁴⁴⁾, it is possible that the large placebo response and/or spontaneous remissions may have masked any beneficial effect of the n-3. Furthermore, the small sample size may also be a reason that this trial should not be viewed as definitive. Thus, the quality and study sizes of research so far have been far less than optimal.

Besides the limitations that were mentioned by the authors, the following limitations further complicate the interpretation of the results of the present meta-analysis. First, the number

of included studies is low. Second, there are large differences among the included studies in terms of treatment (dose, duration, EPA and/or DHA), outcome measure and population (depressed or healthy participants, pregnant and/or post-partum). Heterogeneity, although not statistically significant, is therefore of concern. Due to the low number of included studies, it was not possible to compare subsets of studies. Third, most studies measured a change in the mood or depressive symptoms but not a change in the clinical diagnosis of depression. Fourth, not all studies were designed to address perinatal depression, and consequently these studies may have been underpowered to detect differences in the depression measures. Fifth, per-protocol analyses instead of ITT analyses were used in most studies, which may have increased the chance of finding treatment effects. The fact that a treatment effect was not found suggests that EPA and/or DHA treatment is not effective in treating and/or preventing perinatal depression. Finally, in the studies with non-depressed participants^(35,36,41,43), baseline depressive symptoms were already low. This, combined with a small sample size, has probably resulted in insufficient power to detect small-to-moderate treatment effects in most studies. In conclusion, although currently available data indicate no beneficial effect of n-3 supplementation on

**Fig. 3.** Funnel plot (publication bias assessment) of the effect sizes (Hedges's *g*) according to their standard errors. ◊, Drawn at the pooled effect size; —, expected 95% CI for a given standard error, assuming limited between-study heterogeneity.

the perinatal depression, it may at this stage be too early to draw conclusions.

The available evidence appears to suggest that EPA and/or DHA supplementation is more likely to be beneficial in treating existing symptoms of perinatal depression than in preventing perinatal depression in healthy populations, as is the case for the treatment of depression in general. Sample size may also be an issue; as most included studies were small, it may have been difficult to detect preventative effects. Moreover, the higher severity of depression at baseline also increases statistical power, as the scales used (i.e. BDI, HAM-D and EPDS) are designed to be sensitive in clinically depressed patients and are not very sensitive in detecting changes in the non-pathological range. Future research should include participants with relatively high levels of depressive symptoms (or at high risk of depressive symptoms). It is unclear whether DHA or EPA or their combination may be more effective. The positive study used 2.2 g EPA + 1.2 g DHA daily, suggesting that a high dose of EPA may be important, but in this study, the intervention induced an increase in the erythrocyte DHA level but not in the EPA level. Future studies should provide a complete profile of the oils used, and blood samples should be taken to evaluate the biochemical effects of the intervention. The intervention should be sufficient in dose and duration, and should start when the natural decline in *n*-3 PUFA during pregnancy occurs. Sample sizes should be large enough to detect small-to-moderate effect sizes. A lead-in phase as suggested by Thase⁽⁵⁰⁾ may be helpful to exclude placebo responders and to increase power. Fish consumption should be controlled or included in the analysis, as this variable has the potential to confound the results. Compliance should be monitored, and blinding success should be verified. Furthermore, future studies should provide ITT in addition to per-protocol data. If depressed patients are included, a structured clinical interview should be used to confirm the diagnosis. If self-report questionnaires are used, attention should be paid to the severity of the symptoms because it may be difficult to detect treatment effects in populations with mild symptoms. More preclinical research may be needed to determine the mechanism of action and dose–response characteristics.

In conclusion, on the basis of these findings, EPA and/or DHA cannot be considered to be an empirically supported treatment for perinatal depression as yet. However, the limitations in study quality complicate this interpretation. Well-controlled and larger studies of longer duration are necessary to assess the efficacy of the DHA and EPA in pregnant patients with a major depressive disorder or at high risk for developing depression (e.g. with a history of depression).

Acknowledgements

The authors' responsibilities were as follows: L. A. W. J. performed the literature search and drafted the manuscript; E. J. G. was involved in the conception and design of the study, the statistical analysis and the provision of significant advice; A. J. W. V. d. D. helped in the study supervision, provision of significant advice; all the authors contributed to the data interpretation, critical review and revision of the manuscript. This work was supported by a NWO-VICI grant (no. 453-06-005) to A. J. W. V. d. D., who has also received

research support (€10 000) from Minami Nutrition NV, Antwerp, Belgium, which produces *n*-3 capsules. The other authors report no conflicts of interest.

References

1. Das UN (2008) Folic acid and polyunsaturated fatty acids improve cognitive function and prevent depression, dementia, and Alzheimer's disease – but how and why? *Prostaglandins Leukot Essent Fatty Acids* **78**, 11–19.
2. Kidd PM (2007) Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural–functional synergies with cell membrane phospholipids. *Altern Med Rev* **12**, 207–227.
3. Su KP (2009) Biological mechanism of antidepressant effect of omega-3 fatty acids: how does fish oil act as a 'mind-body interface'? *Neurosignals* **17**, 144–152.
4. Salem N Jr, Litman B, Kim HY, *et al.* (2001) Mechanisms of action of docosahexaenoic acid in the nervous system. *Lipids* **36**, 945–959.
5. Valenzuela A (2009) Docosahexaenoic acid (DHA), an essential fatty acid for the proper functioning of neuronal cells: their role in mood disorders. *Grasas Y Aceites* **60**, 203–212.
6. Farooqui AA, Ong WY & Horrocks LA (2006) Inhibitors of brain phospholipase A₂ activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. *Pharmacol Rev* **58**, 591–620.
7. Edwards R, Peet M, Shay J, *et al.* (1998) Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. *J Affect Disord* **48**, 149–155.
8. Hibbeln JR (1998) Fish consumption and major depression. *Lancet* **351**, 1213.
9. Tanskanen A, Hibbeln JR, Tuomilehto J, *et al.* (2001) Fish consumption and depressive symptoms in the general population in Finland. *Psychiatr Serv* **52**, 529–531.
10. Adams PB, Lawson S, Sanigorski A, *et al.* (1996) Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. *Lipids* **31**, S157–S161.
11. McNamara RK, Hahn CG, Jandacek R, *et al.* (2007) Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. *Biol Psychiatry* **62**, 17–24.
12. Peet M, Murphy B, Shay J, *et al.* (1998) Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. *Biol Psychiatry* **43**, 315–319.
13. Nemets B, Stahl Z & Belmaker RH (2002) Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. *Am J Psychiatry* **159**, 477–479.
14. Peet M & Horrobin DF (2002) A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. *Arch Gen Psychiatry* **59**, 913–919.
15. Su KP, Huang SY, Chiu CC, *et al.* (2003) Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. *Eur Neuropsychopharmacol* **13**, 267–271.
16. Freeman MP, Hibbeln JR, Wisner KL, *et al.* (2006) Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. *J Clin Psychiatry* **67**, 1954–1967.
17. Lin PY & Su KP (2007) A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. *J Clin Psychiatry* **68**, 1056–1061.
18. Marangell LB, Martinez JM, Zboyan HA, *et al.* (2003) A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. *Am J Psychiatry* **160**, 996–998.

19. Rogers PJ, Appleton KM, Kessler D, *et al.* (2008) No effect of *n*-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. *Br J Nutr* **99**, 421–431.
20. Silvers KM, Woolley CC, Hamilton FC, *et al.* (2005) Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. *Prostaglandins Leukot Essent Fatty Acids* **72**, 211–218.
21. Al MD, van Houwelingen AC, Kester AD, *et al.* (1995) Maternal essential fatty acid patterns during normal pregnancy and their relationship to the neonatal essential fatty acid status. *Br J Nutr* **74**, 55–68.
22. Holman RT, Johnson SB & Ogburn PL (1991) Deficiency of essential fatty acids and membrane fluidity during pregnancy and lactation. *Proc Natl Acad Sci U S A* **88**, 4835–4839.
23. Otto SJ, van Houwelingen AC, Badart-Smook A, *et al.* (2001) Comparison of the peripartum and postpartum phospholipid polyunsaturated fatty acid profiles of lactating and nonlactating women. *Am J Clin Nutr* **73**, 1074–1079.
24. Al MD, van Houwelingen AC & Hornstra G (2000) Long-chain polyunsaturated fatty acids, pregnancy, and pregnancy outcome. *Am J Clin Nutr* **71**, 285S–291S.
25. Hibbeln JR & Salem N Jr (1995) Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. *Am J Clin Nutr* **62**, 1–9.
26. Evans J, Heron J, Francomb H, *et al.* (2001) Cohort study of depressed mood during pregnancy and after childbirth. *BMJ* **323**, 257–260.
27. O'Hara MW & Swain AM (1996) Rates and risk of postpartum depression – a meta-analysis. *Int Rev Psychiatry* **8**, 37–54.
28. Makrides M, Neumann MA & Gibson RA (1996) Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition. *Eur J Clin Nutr* **50**, 352–357.
29. Hibbeln JR (2002) Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. *J Affect Disord* **69**, 15–29.
30. Golding J, Steer C, Emmett P, *et al.* (2009) High levels of depressive symptoms in pregnancy with low omega-3 fatty acid intake from fish. *Epidemiology* **20**, 598–603.
31. De Vriese SR, Christophe AB & Maes M (2003) Lowered serum *n*-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered *n*-PUFAs are related to major depression. *Life Sci* **73**, 3181–3187.
32. Browne JC, Scott KM & Silvers KM (2006) Fish consumption in pregnancy and omega-3 status after birth are not associated with postnatal depression. *J Affect Disord* **90**, 131–139.
33. Miyake Y, Sasaki S, Yokoyama T, *et al.* (2006) Risk of postpartum depression in relation to dietary fish and fat intake in Japan: the Osaka Maternal and Child Health Study. *Psychol Med* **36**, 1727–1735.
34. Strom M, Mortensen EL, Halldorsson TI, *et al.* (2009) Fish and long-chain *n*-3 polyunsaturated fatty acid intakes during pregnancy and risk of postpartum depression: a prospective study based on a large national birth cohort. *Am J Clin Nutr* **90**, 149–155.
35. Mattes E, McCarthy S, Gong G, *et al.* (2009) Maternal mood scores in mid-pregnancy are related to aspects of neonatal immune function. *Brain Behav Immun* **23**, 380–388.
36. Krauss-Etschmann S, Shadid R, Campoy C, *et al.* (2007) Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial. *Am J Clin Nutr* **85**, 1392–1400.
37. Chiu CC, Huang SY, Shen WW, *et al.* (2003) Omega-3 fatty acids for depression in pregnancy. *Am J Psychiatry* **160**, 385.
38. Freeman MP, Hibbeln JR, Wisner KL, *et al.* (2006) Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. *Acta Psychiatr Scand* **113**, 31–35.
39. Freeman MP, Hibbeln JR, Wisner KL, *et al.* (2006) An open trial of omega-3 fatty acids for depression in pregnancy. *Acta Neuropsychiatrica* **18**, 21–24.
40. Marangell LB, Martinez JM, Zboyan HA, *et al.* (2004) Omega-3 fatty acids for the prevention of postpartum depression: negative data from a preliminary, open-label pilot study. *Depress Anxiety* **19**, 20–23.
41. Doornbos B, van Goor SA, Dijck-Brouwer DA, *et al.* (2009) Supplementation of a low dose of DHA or DHA+AA does not prevent peripartum depressive symptoms in a small population based sample. *Prog Neuropsychopharmacol Biol Psychiatry* **33**, 49–52.
42. Freeman MP, Davis M, Sinha P, *et al.* (2008) Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. *J Affect Disord* **110**, 142–148.
43. Llorente AM, Jensen CL, Voigt RG, *et al.* (2003) Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. *Am J Obstet Gynecol* **188**, 1348–1353.
44. Rees AM, Austin MP & Parker GB (2008) Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial. *Aust N Z J Psychiatry* **42**, 199–205.
45. Su KP, Huang SY, Chiu TH, *et al.* (2008) Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* **69**, 644–651.
46. Dunstan JA, Mori TA, Barden A, *et al.* (2004) Effects of *n*-3 polyunsaturated fatty acid supplementation in pregnancy on maternal and fetal erythrocyte fatty acid composition. *Eur J Clin Nutr* **58**, 429–437.
47. Freeman MP, Hibbeln JR, Wisner KL, *et al.* (2006) Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. *J Clin Psychiatry* **67**, 1954–1967.
48. Appleton KM, Hayward RC, Gunnell D, *et al.* (2006) Effects of *n*-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. *Am J Clin Nutr* **84**, 1308–1316.
49. Appleton KM, Rogers PJ & Ness AR (2010) Updated systematic review and meta-analysis of the effects of *n*-3 long-chain polyunsaturated fatty acids on depressed mood. *Am J Clin Nutr* **91**, 757–770.
50. Thase ME (1999) How should efficacy be evaluated in randomized clinical trials of treatments for depression? *J Clin Psychiatry* **60**, Suppl. 4, 23–31.